Mr Richard Nagle
Chief Executive Officer
Mr Richard Nagle (Chief Executive Officer) is a life sciences entrepreneur with over 25 years’ experience in the pharmaceutical industry across the US, Europe and Australasia. He was part of the early Innovex HQ team, at the forefront of outsourcing services, where he built and managed the development of large pharmaceutical sales forces, CRA’s and marketing. Innovex was acquired by Quintiles. He was Commercial Director of Walsh/PMSI, which was acquired by IMS Health, the leading supplier of strategic research and data to the pharmaceutical industry.
Moving into drug development, he became Commercial Director of Adelphi Group, responsible for the Strategic Product Development Consultancy, advising global pharmaceutical companies. He was CEO of Cardiac Alert which was acquired by Quintiles. He developed a new drug delivery system for Alza Corporation. The product was subsequently sold to Bayer and is now sold as Duragesic™. He co-founded Melee Venture Management which founded and developed a pain management business, an agri-biotech venture which placed extracted silica into depleted soils in commercial farms, two leading scientifically based cosmetics companies and a wound healing group, Wound Solutions. He joined Metellus, a Swiss-based investment firm, as Partner in 2014, joining the Board of Peptinnovate in 2015.
Mr David Beadle
Chief Business Officer
David Beadle has over 25 years’ experience in the healthcare and finance industries and brings a wealth of knowledge in investment banking, finance and life sciences. David started his career working in the pharmaceutical industry for Schwarz Pharma and Schering AG in marketing and strategic development, where he was part of the global development group for oncology.
He then moved to investment banking where he built and led highly ranked healthcare equity research teams both globally and across Europe. He first joined Hoare-Govett and then moved to UBS AG investment bank where he was a Managing Director in the equities division. He was a leading and highly ranked equity research analyst in the healthcare sector for over 10 years. At UBS, David was the lead analyst on several corporate finance projects, including IPOs and M&A.
David has been a non-executive Director to two successful companies in the healthcare and biotechnology space and has consulted for many others regarding scientific, corporate finance and business development strategies. David was a founding partner of Napa Capital, a corporate finance advisory company, working with several clients regarding financing projects and corporate strategy.
Mr. Michael Albisser
Director/Chief Financial Officer
Michael Albisser (Chief Financial Officer) was previously acting CFO of the controlling unit of a multi-billion dollar single Family Office in Europe, before joining Metellus as a Partner. Extensive experience in accounting, controlling and reporting of investments in all asset classes, including Private Equity, Hedge Funds, industrial and agricultural ventures.
Dr. Anthony Martin
Dr. Anthony Martin (Chairman) has more than 25 years’ experience in the life science industry within the UK and US, in both executive and non-executive roles. Anthony is currently Non-Executive Chairman of PhicoTherapeutics Ltd and a Non-Executive Director of Orthofix International N.V.. He is a Fellow of the Royal Society of Medicine and a member of the Institute of Directors (IoD). He is also Chair and a Trustee of The Martin Reach charity. He was most recently Non-Executive Chairman of Immunodiagnostics Systems Holdings plc and Sphere Medical Holding plc and non-executive at Abcam plc.
His prior executive appointments include CEO of British Bio-Technology Products, AZUR Environmental, Molecular Probes Inc, Celsis International plc and President of Invitrogen Corporation. Anthony’s previous non-executive appointments include Prelude Trust plc, NeuTec Pharma plc and Molecular Insight Pharmaceuticals Inc. He has also served on the main Board of Invitrogen Corporation and the strategic advisory Board of Agilent Technologies. He has extensive experience of governance and responsibilities of Board committees both on UK AIM listed companies and on US Nasdaq listed corporations.
Prof. Clive Page
Prof. Clive Page is Professor of Pharmacology and Director of the Sackler Institute of Pulmonary Pharmacology, King’s College London. Clive’s main research interests are in the pharmacology of inflammation and respiratory disease and he has published over 250 scientific papers. Clive is the co-founder and acted as Chairman of the Board of Verona Pharma plc, an AIM listed Company developing new drugs for the treatment of Respiratory Diseases. He was also a Non-Executive Director of Helperby Therapeutics plc, a spin out Company from St. George’s Hospital Medical School developing novel anti-infective drugs. He is Non-Executive Director of Babraham Biotechnology Ltd, as well as being a Trustee of the Babraham Institute in Cambridge. Clive started his early career in the pharmaceutical industry at Sandoz Ltd, Basel, Switzerland and regularly consults to both the pharmaceutical and biotech Industry. Clive is also the previous Chairman of the Board of Peptinnovate a former Chairman of the Animal Science Group of the Society of Biology and a Council Member of Understanding Animal Research. He was awarded the Society of Biology President’s Medal in 2012.